The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies
Background: Among the several therapeutic options assessed for the treatment of coronavirus disease 2019 (COVID-19), tocilizumab (TCZ), an antagonist of the interleukine-6 receptor, has emerged as a promising therapeutic choice, especially for the severe form of the disease. Proper synthesis of the...
Guardado en:
Autores principales: | Alberto Enrico Maraolo, Anna Crispo, Michela Piezzo, Piergiacomo Di Gennaro, Maria Grazia Vitale, Domenico Mallardo, Luigi Ametrano, Egidio Celentano, Arturo Cuomo, Paolo A. Ascierto, Marco Cascella |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/40df4318293449579a3b4392e929bcbd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Case Report: Tocilizumab for Acute Kidney Graft Dysfunction in Patient Affected by COVID-19
por: Infante Barbara, et al.
Publicado: (2021) -
Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials
por: Dimitrios Sagris, et al.
Publicado: (2021) -
Real World Long-term Assessment of The Efficacy of Tocilizumab in Patients with COVID-19: Results From A Large De-identified Multicenter Electronic Health Record Dataset in the United States
por: Masayuki Nigo, et al.
Publicado: (2021) -
Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
por: Zarębska-Michaluk D, et al.
Publicado: (2021) -
Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study
por: Ohoud Aljuhani, et al.
Publicado: (2021)